Skip to Content

Investor Update

Basel, 12 December 2005

Invitation to conference call on phase III results for MabThera in NHL maintenance
Tuesday 13th December, 2005

We kindly invite you to participate in Roche's conference call to present and discuss the phase III results on the use of MabThera in indolent Non-Hodgkin’s Lymphoma maintenace therapy on

Tuesday 13th December, 2005 from 12:30 to 13:15 CET.


Participants will be:

  • Dr. Karl Mahler, Head of Investor Relations
  • Dr. Andreas Abt, Life Cycle Leader MabThera Oncology
  • Prof. Anton Hagenbeek, Co-Principal Investigator


Analysts and investors are invited to dial in to the conference call using the following dial-in numbers:
+41 (0) 91 610 56 00 (Europe and ROW)
+1 (1) 866 291 41 66 (USA Toll Free)
+44 (0) 207 107 06 11 (UK )

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.

Alternatively, a live audio webcast can be accessed via http://ir.roche.com

Ahead of the call, the presentation will be available from the IR website at http://ir.roche.com.


A replay of the conference call will be available one hour after the conference call, for 48 hours.
Access is by dialling:

+41 91 612 43 30 (Europe and ROW) or
+1 (1) 866 416 25 58 (USA)
+44 207 108 62 33 (UK )
Listeners will be asked to enter the ID 711 followed by the # sign